Print Page | Close Window

Common Cold Cure?

Printed From: Avian Flu Talk
Category: General Discussion
Forum Name: General Discussion
Forum Description: (General discussion regardining new emerging virulent diseases and preparation for the next pandemic)
URL: http://www.avianflutalk.com/forum_posts.asp?TID=37336
Printed Date: November 12 2018 at 12:33pm


Topic: Common Cold Cure?
Posted By: Technophobe
Subject: Common Cold Cure?
Date Posted: May 14 2018 at 3:27pm

Common cold cure on horizon after new drug successfully kills multiple strains of the virus

A cure for the https://www.telegraph.co.uk/foodanddrink/8268871/Why-a-cure-for-the-common-cold-continues-to-elude-us.html" rel="nofollow - common cold is in prospect after British scientists successfully tested  a new drug molecule capable of killing multiple strains of the disease.

Until now it has been nearly impossible to vaccinate against cold virus because the condition is made of up a large family of different https://www.telegraph.co.uk/news/0/australian-flu-prevent-virus-symptoms-look/" rel="nofollow - strains .

Remedies have instead focused on treating symptoms, such as runny nose and sore throat.

But the new approach by researchers at Imperial College London ignored the disease itself, instead targeting the human protein which is “hijacked” by all strains of the virus.

On Monday, leading experts hailed the results, which are published in the journal Nature Chemistry, as holding “great promise” for a practical cure.

The research team will next test the drug in animal trials before moving on to humans.

The common cold accounts for approximately 27 million lost days work a year and, on average, people in the UK spend the equivalent of two and a half years of their life suffering from it.

The compound, codenamed IMP-1088, targets N-myristoyltransferase (NMT), a protein in human cells which cold viruses used to construct a protein “shell”, also known as a capsid, which protects the virus genome.

Because the molecule targets the human protein and not simply a specific virus strand, it should work for all forms of the disease.

Due to the novel way it was created - combining two existing compounds - IMP-1088, is more than 100 times more potent than previous molecules targeting NMT.


The trials found it also succeeded in killing multiple strains, including viruses related to polio and foot and mouth disease.

Professor Ed Tate, who led the research, said: “The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and COPD (chronic obstructive pulmonary disorder).

“A drug like this could be extremely beneficial if given early in infection, and we are working on making a version that could be inhaled, so that it gets to the lungs quickly.”

While there have been previous attempts to create drugs that target human cells rather than the viruses, the side-effects of many were toxic.

By contrast, the new molecule successfully blocked the several strains it was trialed against without damaging the human cells.

However, the safety of the drug will not be established for sure until it has undergone human trials.

Researchers envisage that, in its first formulation, the molecule would be manufactured into a throat spray drug which people would use as a “rescue” drug when symptoms are detected, similar to hay fever medication.

But if they can develop a medication with low toxicity, it may be possible to take it prophylactically in pill form during the Autumn and Winter.

It is likely such a drug would in the first instance be marketed at and trialed on sufferers of asthma and COPD, as this would be the most lucrative for pharmaceutical firms willing to invest in development.

Dr Peter Barlow, British Society for Immunology, said: “While this study was conducted entirely in vitro, i.e. using cells to model Rhinovirus (cold) infection in the laboratory, it shows great promise in terms of eventually developing a drug treatment to combat the effects of this virus in patients.”

The medicinal chemistry team in the Tate group at Imperial, led by Dr Andy Bell, who previously helped invent Viagra, were originally looking for compounds that targeted the protein in malaria parasites.


Source:   https://www.telegraph.co.uk/science/2018/05/14/common-cold-cure-horizon-new-drug-successfully-kills-multiple/" rel="nofollow - https://www.telegraph.co.uk/science/2018/05/14/common-cold-cure-horizon-new-drug-successfully-kills-multiple/



-------------
Absence of proof is not proof of absence.



Replies:
Posted By: Technophobe
Date Posted: May 17 2018 at 2:35am

Cure for common cold? 'Radical' treatment targets humans, not virus. And it works (so far)

http://www.usatoday.com/staff/10046646/josh-hafner/" rel="nofollow - Josh Hafner , USA TODAY Published 3:00 p.m. ET May 16, 2018

A new cold treatment could thwart the virus by leaving it alone and targeting humans instead. The treatment, detailed Monday https://www.nature.com/articles/s41557-018-0039-2.epdf?referrer_access_token=U439ldaoLtVPwdu7SdV2ytRgN0jAjWel9jnR3ZoTv0O1JluMLilDhiT946CzcOe8O2q8wQDQsDutO4h48wtJ5uIiVwC9CaFv0sam4FayH52taC-z2ETtU7xytn1QYN_p9xCpCc8krGOu9Th_dgu1V4bA3KoPE7bYPmsQE4Wqbmrbbf9xZDAv3puc1_f8zXMcSRSpTPrklg5JHk3Z9q0kNw%3D%3D&tracking_referrer=www.bbc.com" rel="nofollow - in Nature Chemistry , blocks a key protein in people that all cold strains need to replicate, upending the infection that's long vexed humanity.

And while a solution to the cold's runny nose and sneezing would be nice, the drug could make a life or death difference. That's according to Ed Tate, a chemist at Imperial College London, who worked on the treatment.

"This could be really helpful for people with health conditions like asthma, who can get quite ill when they catch a cold," Tate http://www.bbc.com/news/health-44107481" rel="nofollow - told the BBC , who called the treatment "a bit radical" for targeting the host, not the virus.

There are hundreds of versions of the cold virus, which the British researchers say makes broad vaccines impossible. And the virus also has a "rapid replication and high mutation rate," they note, meaning it adapts to drugs that target the virus itself.

But all cold viruses share a need for that specific human protein, researchers explain, known as N-myristoyltransferase, or NMT. Block that in humans, they suggest, and you should be able to upend all cold viruses. 

Early lab tests showed the treatment totally halted several cold strains, preventing the virus from latching onto NMT and copying itself to spread.

Those tests used human cells, however, https://www.imperial.ac.uk/news/186270/molecule-that-acts-human-cells-might/" rel="nofollow - the college notes : The team hopes to do animal and human trials later and ensure the treatment is not toxic to the human body. Human trials could start within two years, per the BBC.

"A drug like this could be extremely beneficial if given early in infection," Tate told the college, "and we are working on making a version that could be inhaled, so that it gets to the lungs quickly."

Source:   https://www.usatoday.com/story/news/nation/2018/05/16/cure-common-cold-new-drug-shows-promise-against-cold-virus/615990002/" rel="nofollow - https://www.usatoday.com/story/news/nation/2018/05/16/cure-common-cold-new-drug-shows-promise-against-cold-virus/615990002/




-------------
Absence of proof is not proof of absence.



Print Page | Close Window